Clinical Trials Logo
  1. Home
  2. Treatment Resistant Depression
  3. NCT04101474

Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

Treatment Resistant Depression Clinical Trial

Official title:
Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

Clinical Trial Summary

In this study we will assess the effect of Ketamine infusion on depressive symptoms and in particular its effect on Suicidal behavior, ideation and thoughts in patients with treatment- resistant MDD.

Clinical Trial Description

A Twice repetition of IV infusion of 0.5 mg/kg of ketamine produces an antidepressant response in individuals with treatment-resistant MDD

The work aims to:

1. To assess the onset of action and degree of improvement and the duration of antidepressant effect of ketamine in a sample of patients with treatment -resistant major depressive disorder.

2. To find out whether the onset of Ketamine antidepressant effect is associated with an improvement of suicidality in those patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04101474
Study type Interventional
Source Assiut University
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date December 1, 2019
Completion date February 1, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04124341 - PCS in Severe Treatment Resistant Depression N/A
Recruiting NCT03887715 - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression N/A
Completed NCT04727229 - Stellate Ganglion Block for Major Depressive Disorder. Phase 4
Completed NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) Phase 2
Withdrawn NCT03175887 - Investigational TMS Treatment for Depression N/A
Completed NCT03134066 - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting NCT01984710 - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S N/A
Completed NCT01935115 - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Phase 4
Terminated NCT01687478 - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Phase 3
Completed NCT00531726 - Berlin Deep Brain Stimulation Depression Study N/A
Recruiting NCT04041479 - Biomarker-guided rTMS for Treatment Resistant Depression Phase 3
Recruiting NCT05870540 - BPL-003 Efficacy and Safety in Treatment Resistant Depression Phase 2
Recruiting NCT04959253 - Psilocybin in Depression Resistant to Standard Treatments Phase 2
Completed NCT04856124 - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting NCT03272698 - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression Phase 4
Active, not recruiting NCT04451135 - CET- REM (Correlating ECT Response to EEG Markers) N/A
Recruiting NCT05680220 - 40 Hz Light Neurostimulation for Patients With Depression (FELIX) N/A
Completed NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Recruiting NCT06138691 - KET-RO Plus RO DBT for Treatment Resistant Depression Phase 1
Terminated NCT02675556 - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression Phase 1